Manuscripts
Showing 1554 manuscripts.
Associations of Host Genetic Variants on CD4+ Lymphocyte Count and Plasma HIV-1 RNA in Antiretroviral Naïve Children.
Citation
Singh KK, Fenton T, Apector SA, Qin M, Brummel S. Associations of Host Genetic Variants on CD4+ Lymphocyte Count and Plasma HIV-1 RNA in Antiretroviral Naïve Children.. Pediaric Infectious Disease Journal. 2014. 33: 946-952. PMID: 2797997Year
2014
Journal
Pediaric Infectious Disease Journal
HIV-1 RNA Levels and Antiretroviral Drug Resistance in Blood and Non-blood Compartments from HIV-1-Infected Men and Women Enrolled in AIDS Clinical Trials Group Study A5077.
Citation
RJ Bosch, M Mann, D Katzenstein, S Cu-Uvin, R D'Aquila, L Frenkel, S Fiscus, R Coombs, ACTG A5077 Study Team, R Kantor, D Bettendorf. HIV-1 RNA Levels and Antiretroviral Drug Resistance in Blood and Non-blood Compartments from HIV-1-Infected Men and Women Enrolled in AIDS Clinical Trials Group Study A5077.. PLoS One. 2014. 9: e93537. PMID: 24699474Year
2014
Journal
PLoS One
HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity.
Citation
A Garg, SA Spector. HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity.. Journal of Infectious Diseases. 2014. 209: 441-451. PMID: 23999600Year
2014
Journal
Journal of Infectious Diseases
Are infants unique in their ability to be "functionally cured" of HIV-1
Citation
NH Tobin, GM Aldrovandi. Are infants unique in their ability to be "functionally cured" of HIV-1. Current HIV/AIDS Reports. 2014. 11: 1-10. PMID: 24390641Year
2014
Journal
Current HIV/AIDS Reports
Pharmacokinetic Enhancers in HIV Therapeutics
Citation
C Delille, I Otofokun, EP Acosta, KB Larson, K Wang. Pharmacokinetic Enhancers in HIV Therapeutics. Clinical Pharmacokinetics. 2014. 53: 865-872. PMID: 25164142Year
2014
Journal
Clinical Pharmacokinetics
Pharmacokinetics, Safety, and 48-Week Efficacy
of Oral Raltegravir in HIV-1–Infected Children
Aged 2 Through 18 Years
Citation
Edward P Acosta, Hedy Teppler, Brenda Homony, Bobbie Graham, Terence Fenton, Xia Xu, Larissa Wenning, Stephen A Spector, Lisa M Frenkel, Carmelita Alvero, Carol Worrell, Edward Handelsman, Andrew Winzia, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team, Sharon Nachman, Nan Zheng. Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1–Infected Children Aged 2 Through 18 Years. Clinical Infectious Diseases. 2014. 58: 413-422. PMID: 24145879Year
2014
Journal
Clinical Infectious Diseases
Study
P1066
Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission
Citation
Avy Violari, Paul Palumbo, Susan H Eshleman, International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1060 Study Team, Elaine J Abrams, Mutsa Bwakura-Dangarembizi, Linda Barlow-Mosha, Portia Kamthunzi, Pauline M Sambo, Mark F Cotton, Harry Moultrie, Sandhya Khadse, Werner Schimana, Raziya Bobat, Bonnie Zimmer, Elizabeth Petzold, Jane C Lindsey, Lynne M Mofenson, Michael D Hughes, Patrick Jean-Philippe. Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. Pediaric Infectious Disease Journal. 2014. 33: 846-854. PMID: 25222305Year
2014
Journal
Pediaric Infectious Disease Journal
Study
P1060
Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation
Citation
Nigel J Klein, Joanna Lewis, Ann J Melvin, Gareth Tudor-Williams, Ross E McKinney Jr, PENPACT-1 (PENTA 9/PACTG 390) Study Team, Dwight E Yin, Meredith G Warshaw, William C Miller, Hannah Castro, Susan A Fiscus, Lynda M Harper, Linda J Harrison. Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation. 2014. PMID: 25266426Year
2014
Discordant associations between SLCO1B1 521T¿C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146
Citation
Discordant associations between SLCO1B1 521T¿C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146. Therapeutic Drug Monitoring. 2013. 35: 209-216. PMID: 23503447Year
2013
Journal
Therapeutic Drug Monitoring
Participation and retention of youth with perinatal HIV infection in mental health research studies: the IMPAACT P1055 Psychiatric Comorbidity Study
Citation
Participation and retention of youth with perinatal HIV infection in mental health research studies: the IMPAACT P1055 Psychiatric Comorbidity Study. Journal of Acquired Immune Deficiency Syndromes. 2013. 63: 401-9. PMID: 23714737Year
2013
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1055